Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3324MR)

This product GTTS-WQ3324MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3324MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1572MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-083
GTTS-WQ1523MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-031
GTTS-WQ8666MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ14808MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-70
GTTS-WQ8479MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HTI-1088
GTTS-WQ12671MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ14766MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SGN-35
GTTS-WQ12835MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ONC-005
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW